Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
APGE
Stock Latest News
Ratings
Michael Yee Reaffirms Buy on Apogee, Citing Differentiated Zumilokibart Profile, Upcoming Data Catalysts, and Maintained $100 Price Target
11d ago
APGE
Premium
Ratings
Analyst Reiterates Buy on Apogee, Maintains $137 Price Target on Strong Zumilokibart Profile and Pipeline Upside
11d ago
APGE
Premium
The Fly
Apogee Therapeutics initiated with a Buy at Rothschild & Co Redburn
22d ago
APGE
Premium
Company Announcements
Apogee Therapeutics Announces Upcoming Board Resignations, Governance Shift
29d ago
8K
APGE
Premium
Ratings
APGE: Best-in-Class Potential for Zumilokibart in Atopic Dermatitis Supports Undervalued Buy Rating
2M ago
APGE
Premium
The Fly
Apogee Therapeutics price target raised to $110 from $105 at Mizuho
2M ago
APGE
Premium
Company Announcements
Apogee Therapeutics Prices Upsized Public Equity Offering
2M ago
8K
APGE
Premium
The Fly
Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
2M ago
GM
AMD
Premium
The Fly
Apogee Therapeutics 5M share Secondary priced at $70.00
2M ago
APGE
Premium
The Fly
Apogee Therapeutics price target raised to $118 from $108 at Deutsche Bank
2M ago
APGE
Premium
The Fly
Apogee Therapeutics price target raised to $160 from $130 at Guggenheim
2M ago
APGE
Premium
The Fly
Apogee Therapeutics price target raised to $125 from $95 at Citi
2M ago
APGE
Premium
The Fly
Apogee Therapeutics price target raised to $130 from $89 at Canaccord
2M ago
APGE
Premium
Ratings
Apogee Therapeutics: Strong Phase IIa IL‑13 Data Support Buy Rating and Long-Term Upside in Atopic Dermatitis
2M ago
APGE
Premium
Ratings
APGE: Zumilokibart’s Best-in-Class Atopic Dermatitis Profile and Long-Acting Dosing Support Buy Rating and Re-Rating Potential
2M ago
APGE
Premium
The Fly
Apogee Therapeutics announces $300M common stock offering
2M ago
APGE
Premium
Market News
Morning News Wrap-Up 3/23/26: Today’s Biggest Stock Market Stories!
2M ago
EA
HD
Premium
The Fly
Apogee Therapeutics rises 22.9%
2M ago
APGE
Premium
The Fly
Midday Fly By: Musk to start Terafab project, Elliott takes stake in Synopsys
2M ago
MP
DBX
Premium
The Fly
Apogee Therapeutics price target raised to $131 from $99 at BofA
2M ago
APGE
Premium
The Fly
Apogee Therapeutics rises 17.9%
2M ago
APGE
Premium
Market News
Why Did Apogee Therapeutics Stock (APGE) Soar Today?
2M ago
APGE
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
